Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccine Booster with/without GM-CSF in Melanoma
NCT00184067Phase 2Terminated
- Sponsor
- University of Southern California
- Start
- May 2004
- Primary completion
- Apr 2007
- Modality
- Whole Cell Cancer Vaccines, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of tyrosinase + gp100 + mart-1, sargramostim in melanoma, sponsored by University of Southern California. Started May 2004; status: terminated.
02
Drugs
tyrosinase + gp100 + mart-1sargramostim
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00184067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00184067.